IPIRA Impact

Faster, More, Better, Creative

Deals that make sense, don't get us in trouble, and uphold our mission and principles

  • "Preferred partner" —Dow
  • "One of five best" —Inc. Magazine
  • "Breakthrough business model" —National Academy of Sciences Institute of Medicine
  • Deal of Distinction —Licensing Executives Society
  • Patents for Humanity award —US Patent and Trademark Office
  • Legacy Award 2016 —East Bay Economic Development
  • Highest Number of Startups Formed Among Universities — Pitchbook
  • Second Highest Number of Entrepreneurs — PitchBook


in Funds raised

including more than $1 Billion in Industry Sponsored Research and over $250M in Licensing Revenue.


Products commercialized

from discoveries licensed through IPIRA such as of treatment for malaria and cancer, biofuels, robotic legs, DNA sequencing, surgical tools, forensic tools, handheld diagnostics, gene editing, mobile microscopy, nanowires, RFID, internet security software, search engines and more.


Startups founded

to commercialize inventions and copyrights under licenses from IPIRA, attracting $1.6B in venture funding and $51M in SBIR/STTR grants since 2005. 35 Startups have had a successful exit via merger or acquisition, totaling $8.1B in cash and stock options, while 66 Berkeley startups currently in the Bay Area employ 1,543 Californians & generate $195M in annual revenue.


Companies served

through negotiated agreements with IPIRA, including $500M in industry sponsored research from British Petroleum for the Energy Biosciences Institute, >$5M in industry sponsored research from Aduro, and $89M in licensing revenue from Bristol-Myers Squibb.


UC Berkeley has the 2nd highest percentage of industry sponsored research when compared to other research institutions. Click on a link below to view one of the many success stories that IPIRA has helped create.


Innovations Funded by State Assembly Bill AB2664: Highlights


Learn More